Related references
Note: Only part of the references are listed.FGFR3 and PIK3CA mutations in stucco keratosis and dermatosis papulosa nigra
C. Hafner et al.
BRITISH JOURNAL OF DERMATOLOGY (2010)
Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice
Jing Qing et al.
JOURNAL OF CLINICAL INVESTIGATION (2009)
Activating mutations in FGFR3 and HRAS reveal a shared genetic origin for congenital disorders and testicular tumors
Anne Goriely et al.
NATURE GENETICS (2009)
Nordihydroguaiaretic acid inhibits an activated fibroblast growth factor receptor 3 mutant and blocks downstream signaling in multiple myeloma cells
April N. Meyer et al.
CANCER RESEARCH (2008)
Effect of PPADS on achondroplasic chondrocytes:: Inhibition of FGF receptor type 3 over-activity
Ana Guzman-Aranguez et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2008)
STAT1 and STAT3 do not participate in FGF-mediated growth arrest in chondrocytes
Pavel Krejci et al.
JOURNAL OF CELL SCIENCE (2008)
Simple, mammalian cell-based assay for identification of inhibitors of the Erk MAP kinase pathway
Pavel Krejci et al.
INVESTIGATIONAL NEW DRUGS (2007)
Bisindolylmaleimide I suppresses fibroblast growth factor-mediated activation of Erk MAP kinase in chondrocytes by preventing Shp2 association with the Frs2 and Gab1 adaptor proteins
Pavel Krejci et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
MIP-1α (CCL3) is a downstream target of FGFR3 and RAS-MAPK signaling in multiple myeloma
Esther Masih-Khan et al.
BLOOD (2006)
Mosaicism of activating FGFR3 mutations in human skin causes epidermal nevi
Christian Hafner et al.
JOURNAL OF CLINICAL INVESTIGATION (2006)
The suramin analog 4,4′,4,4′-(carbonylbis(imino-5,1,3-benzenetriylbis (carbonylimino)))tetra-kis-benzenesulfonic acid (NF110) potently blocks P2X3 receptors:: Subtype selectivity is determined by location of sulfonic acid groups
Ralf Hausmann et al.
MOLECULAR PHARMACOLOGY (2006)
Understanding the mechanism of the antimitogenic activity of suramin
KM Kathir et al.
BIOCHEMISTRY (2006)
Interaction of fibroblast growth factor and C-natriuretic peptide signaling in regulation of chondrocyte proliferation and extracellular matrix homeostasis
P Krejci et al.
JOURNAL OF CELL SCIENCE (2005)
A protein canyon in the FGF-FGF receptor dimer selects from an a la carte menu of heparan sulfate motifs
M Mohammadi et al.
CURRENT OPINION IN STRUCTURAL BIOLOGY (2005)
Cell responses to FGFR3 signalling:: growth, differentiation and apoptosis
CGM L'Hôte et al.
EXPERIMENTAL CELL RESEARCH (2005)
Structure-activity relationships of analogues of NF449 confirm NF449 as the most potent and selective known P2X1 receptor antagonist
MU Kassack et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2004)
FGF2 inhibits proliferation and alters the cartilage-like phenotype of RCS cells
P Krejci et al.
EXPERIMENTAL CELL RESEARCH (2004)
Overexpression of CNP in chondrocytes rescues achondroplasia through a MAPK-dependent pathway
A Yasoda et al.
NATURE MEDICINE (2004)
Fibroblast growth factor receptor-3 as a therapeutic target for achondroplasia - Genetic short limbed dwarfism
D Aviezer et al.
CURRENT DRUG TARGETS (2003)
A network of transcriptional and signaling events is activated by FGF to induce chondrocyte growth arrest and differentiation
L Dailey et al.
JOURNAL OF CELL BIOLOGY (2003)
Structural basis for activation of fibroblast growth factor signaling by sucrose octasulfate
BK Yeh et al.
MOLECULAR AND CELLULAR BIOLOGY (2002)
Nature of interaction between basic fibroblast growth factor and the antiangiogenic drug 7,7-(carbonyl-bis[imino-N-methyl-4,2-pyrrolecarbonylimino[N-methyl-4,2-pyrrole]-carbonylimino])-bis-(1,3-naphtalene disulfonate).: II.: Removal of polar interactions affects protein folding
M Zamai et al.
BIOPHYSICAL JOURNAL (2002)
NF449:: a subnanomolar potency antagonist at recombinant rat P2X1 receptors
K Braun et al.
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY (2001)
Fibroblast growth factor inhibits chondrocytic growth through induction of p21 and subsequent inactivation of cyclin E-Cdk2
T Aikawa et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Analysis of FGFR3 gene mutations in multiple myeloma patients with t(4;14)
D Intini et al.
BRITISH JOURNAL OF HAEMATOLOGY (2001)
Deregulated FGFR3 mutants in multiple myeloma cell lines with t(4;14): comparative analysis of Y373C, K650E and the novel G384D mutations
D Ronchetti et al.
ONCOGENE (2001)
Fibroblast growth factors and their inhibitors
F Manetti et al.
CURRENT PHARMACEUTICAL DESIGN (2000)
Crystal structure of a ternary FGF-FGFR-heparin complex reveals a dual role for heparin in FGFR binding and dimerization
J Schlessinger et al.
MOLECULAR CELL (2000)
Share Paper
